462510.KQ
LAMEDITECH Co., Ltd.
KOE · Healthcare · Medical - Specialties · KR
KRW 2,610.00
−5.26%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 5.6B | 7.2B | 6.6B | 2.9B | 2.1B |
| Cost of Revenue | 3.5B | 4.0B | 4.5B | 2.0B | 1.8B |
| Gross Profit | 2.1B | 3.1B | 2.1B | 899.4M | 284.8M |
| Operating Expenses | |||||
| R&D Expense | 1.6B | 1.7B | 1.5B | 765.3M | 1.3B |
| SG&A Expense | 9.7B | 8.9B | 7.9B | 2.0B | 1.3B |
| General & Admin Expense | 662.3M | 814.7M | 504.7M | 453.8M | 354.1M |
| Selling & Marketing Expense | 5.8B | 8.0B | 7.4B | 1.6B | 912.4M |
| Other Expenses | 3.2B | 4.5B | 2.4B | 1.6B | 21.6M |
| Total Operating Expenses | 12.9B | 15.0B | 11.8B | 4.4B | 3.6B |
| Cost and Expenses | 16.4B | 19.0B | (16.2B) | 6.4B | 5.4B |
| Operating Income (EBIT) | (10.8B) | (11.8B) | (9.7B) | (3.5B) | (3.3B) |
| Non-Operating | |||||
| Interest Income | 970.0M | 1.0B | 226.0M | 94.0M | 11.6M |
| Interest Expense | 923.0M | 543.7M | 59.7M | 977.0M | 1.0B |
| Net Interest Income | 47.0M | 468.4M | 166.3M | (883.0M) | (994.3M) |
| Other Non-Op Income/Expense | 1.1B | 476.4M | 177.9M | (4.8B) | (1.1B) |
| Non-Operating Income (excl Interest) | (499.6M) | — | (237.7M) | 3.8B | 80.4M |
| EBT (Pre-Tax Income) | (9.8B) | (11.4B) | (9.5B) | (8.3B) | (4.4B) |
| Income Tax Expense | — | — | — | — | 30.0M |
| Bottom Line | |||||
| Net Income | (9.8B) | (11.4B) | (9.5B) | (8.3B) | (4.4B) |
| Earnings from Cont. Ops | (9.8B) | (11.4B) | (9.5B) | (8.3B) | (4.4B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (9.8B) | (11.4B) | (9.5B) | (8.3B) | (4.4B) |
| Per Share | |||||
| Basic EPS | (₩1,110) | (₩1,299) | (₩1,177) | (₩960) | (₩512) |
| Diluted EPS | (₩1,110) | (₩1,299) | (₩1,177) | (₩960) | (₩512) |
| Revenue Per Share | ₩632 | ₩821 | ₩816 | ₩337 | ₩238 |
| Shares | |||||
| Basic Shares Outstanding | 8.8M | 8.8M | 8.1M | 8.7M | 8.7M |
| Diluted Shares Outstanding | 8.8M | 8.8M | 8.1M | 8.7M | 8.7M |
| Profitability Metrics | |||||
| EBITDA | (10.4B) | (11.2B) | (9.0B) | (7.0B) | (3.2B) |
| D&A | 609.9M | 595.1M | 464.9M | 296.1M | 235.1M |
| EBIT | (10.8B) | (11.8B) | (9.4B) | (7.3B) | (3.4B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026